ADVANCED CELL THERAPY AND RESEARCH INSTITUTE, SINGAPORE

Business Description

ADVANCED CELL THERAPY AND RESEARCH INSTITUTE, SINGAPORE is registered as a business entity on 20 April 2020 (4.7 years ago) structured as a Sole Proprietor with 1 officer(s) in-charge. The business jurisdiction is overseen by the Accounting and Corporate Regulatory Authority (ACRA), a government agency from Singapore with the given Business Registration Number / Unique Entity Number (UEN) 53412298A. The business official address is located at 23 Rochester Park #06-01, Singapore 139234 with main trading activity as Develop Gmp Compliant Manufacturing Process For Cellular-based Therapeutics in the primary industry of 21022: Manufacture Of Other Biological Products And Preparations For Human Use using Singapore Dollars - SGD as its default trading currency. The business name remains unchanged since inception. The business annual account filing date falls on 20 April and is currently operational with the status of 'Live'.

In the past 365 days, ADVANCED CELL THERAPY AND RESEARCH INSTITUTE, SINGAPORE has received a total of Login to view reported payment review(s). 4 were rated Good and Login to view were rated Poor. The latest review was made on 2023-06-21 and it was reported "Good". The aggregated good payment amount is equivalent to USD 1,244, and aggregated poor payment amount is equivalent to USD Login to view. Its current payment rating of "A" suggest a healthy payment culture where settlement with stakeholders is always prioritised. Since the business is currently active, it also signals positive financial standing. The lack of an appointed auditor indicates that the business is small sized as it did not meet the regulatory requirements of revenue or assets exceeding SGD 10 million, or has more than 50 employees in the previous two fiscal years.

ADVANCED CELL THERAPY AND RESEARCH INSTITUTE, SINGAPORE is not yet a Prompt Payment Initiative Signatory.

Last updated on 30 April 2023